Sinopharm Group Co (SHTDY)
OTHER OTC:SHTDY
Want to see SHTDY full AI Analyst Report?
SHTDY Stock Chart & Stats
$13.13
-$0.11(-0.80%)
At close: 4:00 PM EST
$13.13
-$0.11(-0.80%)
Day’s Range― - ―
52-Week Range$11.59 - $14.04
Previous CloseN/A
Volume2.10K
Average Volume (3M)1.38K
Market Cap
$7.65B
Enterprise Value$97.25B
Total Cash (Recent Filing)$47.16B
Total Debt (Recent Filing)$93.29B
Price to Earnings (P/E)7.8
Beta0.26
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.75%
Share Statistics
EPS (TTM)N/A
Shares Outstanding268,362,150
10 Day Avg. Volume773
30 Day Avg. Volume1,375
Financial Highlights & Ratios
PEG Ratio-4.39
Price to Book (P/B)0.64
Price to Sales (P/S)0.10
P/FCF Ratio4.32
Enterprise Value/Market Cap12.71
Enterprise Value/Revenue0.17
Enterprise Value/Gross Profit2.26
Enterprise Value/Ebitda4.72
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Nationwide Logistics & Sales NetworkA nationwide logistics and sales network is a durable competitive asset in healthcare distribution. It lowers fulfillment costs, supports reliable delivery for hospitals and pharmacies, and creates switching costs for customers and suppliers, sustaining revenue and tender competitiveness over months.
Diversified Revenue StreamsMultiple revenue channels (wholesale pharmaceuticals, devices/consumables, and retail pharmacies) reduce dependence on any single product or buyer. This structural diversification cushions policy or tendering swings and supports steadier cashflows across 2–6 months and longer.
Strong Cash ConversionEarnings translating into cash consistently indicates healthy cash-generation for a distribution business. Reliable cash conversion supports working capital needs, dividends, and potential deleveraging or targeted investments, preserving operational flexibility over the medium term.
Bears Say
Rising LeverageA meaningful rise in leverage reduces financial flexibility and raises interest-cost sensitivity. For a low-margin distributor, higher debt amplifies earnings volatility, constrains capital allocation for logistics/technology upgrades, and increases risk during weaker demand periods.
Revenue WeaknessFalling revenue after prior growth suggests margin pressure or market share loss in core distribution. Persistent top-line decline erodes operating leverage, limits reinvestment, and makes sustaining retail expansion or service investments harder across the coming quarters.
Compressed Margins And Thin ProfitabilityLow and declining margins leave little buffer for cost increases or pricing pressure. Thin profitability limits retained earnings, reduces ROE, and constrains the firm's ability to absorb regulatory or procurement shifts, making long-term margin recovery more challenging.
Sinopharm Group Co News
SHTDY FAQ
What was Sinopharm Group Co’s price range in the past 12 months?
Sinopharm Group Co lowest stock price was $11.59 and its highest was $14.04 in the past 12 months.
What is Sinopharm Group Co’s market cap?
Sinopharm Group Co’s market cap is $7.65B.
When is Sinopharm Group Co’s upcoming earnings report date?
Sinopharm Group Co’s upcoming earnings report date is Aug 31, 2026 which is in 125 days.
How were Sinopharm Group Co’s earnings last quarter?
Currently, no data Available
Is Sinopharm Group Co overvalued?
According to Wall Street analysts Sinopharm Group Co’s price is currently Overvalued.
Does Sinopharm Group Co pay dividends?
Sinopharm Group Co pays a Annually dividend of $0.471 which represents an annual dividend yield of 3.75%. See more information on Sinopharm Group Co dividends here
What is Sinopharm Group Co’s EPS estimate?
Sinopharm Group Co’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sinopharm Group Co have?
Sinopharm Group Co has 268,362,150 shares outstanding.
What happened to Sinopharm Group Co’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sinopharm Group Co?
Currently, no hedge funds are holding shares in SHTDY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sinopharm Group Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.49%
12-Months-Change
Fundamentals
Return on Equity
8.62%
Trailing 12-Months
Asset Growth
3.79%
Trailing 12-Months
Company Description
Sinopharm Group Co
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---